Open access peer-reviewed chapter

OCT Findings in Myopic Traction Maculopathy

By Ramesh Venkatesh, Bharathi Bavaharan and Naresh Kumar Yadav

Submitted: October 1st 2018Reviewed: December 21st 2018Published: May 11th 2019

DOI: 10.5772/intechopen.83766

Downloaded: 171

Abstract

The prevalence of myopia is constantly on a rise. Patients with high myopia and pathological myopia can lose vision due to a number of degenerative changes occurring at the macula. With recent advances in imaging techniques such as spectral domain optical coherence tomography (OCT) and swept-source OCT, our understanding of macular pathology in myopia has improved significantly. New conditions such as myopic traction maculopathy have been identified and defined. Treatment approaches are now being planned on the basis of the pathoanatomy of myopic traction maculopathy on OCT. In this chapter, we discuss the role of OCT imaging in myopic traction maculopathy.

Keywords

  • myopia
  • traction maculopathy
  • posterior staphyloma

1. Introduction

Myopic traction maculopathy was first described by Panozza and associates in 2004 as a group of pathological features seen in eyes with high myopia generated by traction [1]. In recent times, MTM is also termed as myopic foveoschisis. One of the important reasons for reduced vision in these myopic eyes is traction-related retinal disorders. Eyes with myopic traction maculopathy demonstrate features of vitreomacular traction, retinal thickening, macular retinal schisis-like thickening, lamellar macular hole (MH), and foveal retinal detachment (FRD)[2]. Many of these retinal pathologies are not detectable on clinical examination and are only found on advanced imaging with optical coherence tomography. Because of the clinical subtlety of some of these disorders, decreased visual acuity may be attributed to other causes, whereas macular traction may remain undiagnosed [3, 4, 5, 6, 7, 8]. The natural course of myopic macular traction disorders is not clear. Some studies have shown progression to more serious complications like full-thickness MH and FRD while a few studies have shown spontaneous resolution of foveal detachment and macular retinoschisis after development of spontaneous posterior vitreous detachment (PVD) [6, 9, 10, 11, 12, 13]. Optical coherence tomography (OCT) is a useful, non-invasive and indispensable tool in the diagnosis, pathogenesis, staging, prognosis, treatment and follow-up of MTM. In this article, we describe the role of OCT imaging in MTM.

2. Pathogenesis

Before the advent of OCT, the anatomic features of MTM were not described and the pathogenesis was poorly understood. Both TD-OCT and SD-OCT studies have provided an invaluable contribution to the characterization and understanding of the underlying pathologic mechanism involved in MTM. There are four major traction mechanisms identified in MTM: (1) Peri foveal vitreomacular traction (2) Cortical vitreous remnants after (PVD) development (3) Epiretinal membrane formation (4) Intrinsic non-compliance of the internal limiting membrane (ILM) and inner retina to conform to the shape of the posterior staphyloma [14, 15]. The first three mechanisms constitute the extrinsic forces (outside the retina) responsible for MTM while the stiff ILM and inner retinal layers constitute the intrinsic force (within the retina) responsible for MTM formation. The ILM itself can cause traction in eyes with posterior staphyloma. It appears that in eyes without identifiable preretinal tractional elements, ILM peeling resolves the retinal thickening. There are two possible explanations: One is that the ILM is highly elastic and tough, rendering it taut like a drum. In eyes with posterior staphyloma, the ILM is like the surface of a drum and is relatively resistant to permanent deformation and stretching. The second, more probable, explanation is that microscopic cellular and collagen proliferation develops on the ILM surface after PVD causing the ILM to be less distensible and making it more rigid. This prevents the ILM to conform to the contour of the posterior staphyloma and causes a schisis-like retinal thickening [16]. Understanding the pathogenetic mechanism responsible for MTM formation helps in deciding the surgical approach in these eyes (Figure 1).

Figure 1.

Mechanisms causing MTM. (a) MTM caused by vitreomacular traction with presence of foveal retinal detachment (FRD). (b) Epiretinal membrane causing schisis-like retinal thickening with associated FRD. (c) MTM with no apparent preretinal membranes. (d) Tenting of the inner retina at the retinal arteriole (black arrow) with complete resolution of the retinal thickening following vitrectomy in MTM.

3. Diagnosis

Myopic tractional maculopathy is virtually seen in eyes with posterior staphyloma. In a study using SD-OCT, Henaine-Berra et al. [17] identified MTM in 17 of 116 eyes of pathological myopia, thus reporting a prevalence of approximately 15%. Some of these retinal changes are difficult to appreciate in eyes with high myopia due to the presence of the pathological degenerative changes at the posterior pole. Decreased visual acuity in these eyes is usually attributed to causes other than macular traction. OCT is often used in identifying the different retinal pathologies like vitreomacular traction, retinal thickening, macular retinoschisis, lamellar MH, and FRD. Progression of the myopic tractional detachment to develop a full-thickness MH and macular retinal detachment can also be identified with use of OCT.

4. Staging and classification

On the basis of OCT, Shimada et al. [4] have classified MTM into five stages from S0 to S4. This staging is based on the location of retinoschisis and its extent of macular involvement (Table 1).

StageLocation and involvement
0No retinoschisis
1Extrafoveal
2Foveal
3Both foveal and extrafoveal but not the entire macula
4Entire macula

Table 1.

Staging of myopic tractional maculopathy depending on the extent of involvement.

Shimada et al. [4] further defined the progression as an increase of the extent or height of retinoschisis (more than 100 μm) or the development of an inner lamellar MH, FRD, or full-thickness MH. During a mean follow-up of 36.2 months, they reported progression in 11.6% (24/207) eyes, which included 0.9% who progressed to full-thickness MH and 3.4% who progressed to FRD. The eyes with extensive macular retinoschisis (S4) showed progression significantly more (42.9%) than eyes having less extensive macular retinoschisis areas (6.7%). Six (21.4%) of 28 eyes with S4 MTM progressed to foveal detachment (Figures 2 and 3).

Figure 2.

(a–d) Progression of MTM leading to FRD over a period of 5 years.

Figure 3.

(a–c) Progression of MTM in the fellow eye of a patient who had undergone vitrectomy for MTM with foveal detachment in the other eye.

5. Treatment

The goal of treatment in MTM is to relieve the tractional forces responsible for the formation of MTM [18]. This can be achieved primarily with the help of internal procedure with vitrectomy and external procedure with macular buckle. Pharmacologic vitreolysis can be considered a useful treatment option if vitreomacular traction from the perifoveal PVD or traction associated with a remnant cortical vitreous layer after PVD is responsible for the MTM formation.

The indications of surgery in MTM are:

  1. Recent onset reduction in visual acuity secondary to development of full-thickness MH or FRD.

  2. Progression in the extent of the schisis-like thickening documented by OCT.

  3. Vision <20/50.

Most surgeons while dealing with myopic traction maculopathy have two approaches:

  1. Minimalist approach—This involves identifying and resolving only the major traction mechanism visible on OCT. In this approach, only vitrectomy with PVD induction is carried out. ILM peeling is not done in these cases. This avoids complications of ILM peeling in select eyes, but it is unlikely to be successful in each and every case.

  2. Comprehensive approach—In this approach, all the preretinal tractional elements are removed along with ILM peeling in every case. This approach has the highest single-operation success rate and ensures complete removal of all cellular and vitreous components that might cause current or future traction [14].

Taniuchi et al. [19] evaluated the effect of vitrectomy with and without ILM peeling in 71 eyes of 64 patients with myopic traction maculopathy. They studied the effects on visual acuity and post-operative complications. The results indicated that vitrectomy with ILM peeling can lead to improvement in vision in patients with macular retinoschisis or foveal detachment. Recurrences of tractional macular detachment were also more frequent in eyes without ILM peeling.

5.1 Surgical techniques

Basically, vitrectomy with removal of the posterior cortical vitreous is what is minimally required in relieving the tractional forces responsible for MTM formation. The role of additional procedures like peeling of internal limiting membrane and use of gas tamponade in MTM is debatable. In eyes with MTM secondary to vitreomacular traction from the perifoveal PVD and traction associated with a remnant cortical vitreous layer after PVD, vitrectomy alone with removal of posterior cortical vitreous is sufficient in relieving the traction and achieves a normal retinal anatomy. In eyes with MTM secondary to epiretinal membrane formation, additional removal of epiretinal membrane is required. MTM caused by intrinsic stiffening of the ILM requires peeling of ILM with or without the placement of macular buckle [20, 21]. Few studies have shown that sparing a small island of ILM over the fovea in eyes with MTM can prevent the development of post-operative MHs which are usually difficult to fix [22, 23] (Table 2).

MTMSurgery procedure
(1) Due to vitreomacular traction from the perifoveal PVDVitrectomy with posterior cortical vitreous removal
(2) Due to traction associated with a remnant cortical vitreous layer after PVDVitrectomy with posterior cortical vitreous removal
(3) Due to epiretinal membrane formationVitrectomy with posterior cortical vitreous removal with ERM removal
(4) Due to intrinsic stiffening of the ILM(a) Vitrectomy with posterior cortical vitreous removal with ILM peeling
(b) Macular buckle alone
(c) combined vitrectomy and macular buckle
(5) With associated full-thickness MH or FRD(a) Vitrectomy with posterior cortical vitreous removal with ILM peeling with gas tamponade
(b) Macular buckle alone
(c) Combined vitrectomy and macular buckle

Table 2.

Surgical decision-making in myopic traction maculopathy based on pathoanatomy seen on optical coherence tomography.

Abbreviations: MTM—myopic traction maculopathy; PVD—posterior vitreous detachment; ERM—epiretinal membrane; ILM—Internal limiting membrane; MH—Macular hole; FRD—Foveal retinal detachment.

Common difficulties encountered during vitrectomy in these high myopic eyes are: (1) inability of the smaller gauge instruments to reach the retinal tissue at the macula due to longer axial length; (2) In eyes with posterior staphyloma, the vitreous is strongly adherent to the edge of the staphyloma resulting in retinal breaks during PVD induction; (3) Staining of ILM with various dyes is usually inadequate and patchy making ILM peeling difficult in these scenarios; (4) Glaucoma is associated with high myopia resulting in an already compromised optic nerve head which can get worsened following vitrectomy; (5) Scleral thinning associated with high myopia can lead to catastrophic complications like expulsive hemorrhage. Thus, macular buckle has emerged as a useful and effective treatment option in the management of MTM. However, due to the longer learning curve of this technique and unpredictable outcomes following this procedure, vitrectomy still remains the most preferred treatment modality amongst most vitreoretinal surgeons in the management of MTM.

6. Monitoring

Following surgery for MTM, resolution of retinal thickening and/or foveal detachment is monitored using OCT. Complete resolution of retinal thickness or subretinal fluid is achieved in 6–9 months after surgery [24] (Figure 4). Patients with high myopia and unilateral MTM require regular OCT monitoring of the fellow eye to assess progression to myopic pre-MTM [25].

Figure 4.

(a–b) Pre and post-operative images of a patient with myopic foveoschisis with FRD. At 6 months post-op, there is complete resolution of the retinal thickening and subretinal fluid.

7. Conclusion

One of the important causes for disturbed vision secondary to high myopia is MTM. It may be difficult to appreciate MTM on clinical examination with biomicroscopy. With the advent of OCT, the diagnosis of MTM and a posterior staphyloma can be made easily. Newer generation OCT imaging modalities have helped in the understanding the mechanism of myopic foveoschisis formation and help in deciding the treatment plan by the retinal surgeon. Early detection and referral to a retinal specialist for evaluation and treatment when appropriate may prevent further vision loss secondary to MH formation and/or retinal detachment.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Ramesh Venkatesh, Bharathi Bavaharan and Naresh Kumar Yadav (May 11th 2019). OCT Findings in Myopic Traction Maculopathy, A Practical Guide to Clinical Application of OCT in Ophthalmology, Michele Lanza, IntechOpen, DOI: 10.5772/intechopen.83766. Available from:

chapter statistics

171total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

A Practical Guide to Clinical Application of OCT in Ophthalmology

Edited by Michele Lanza

Next chapter

Intraoperative OCT for Monitoring Corneal Pachymetry during Corneal Collagen Cross-Linking for Keratoconus

By Reza Ghaffari, Hassan Hashemi and Soheila Asghari

Related Book

First chapter

Novel Insight into Morphological Features and Vascular Profile of Selected Macular Dystrophies Using Swept-Source Optical Coherence Tomography and Optical Coherence Tomography Angiography

By Magdy Moussa and Mahmoud Leila

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us